Israeli pharmaceutical company Protalix Biotherapeutics Inc. has announced today that it has signed an agreement with Fundação Oswaldo Cruz (Fiocruz), an arm of Brazil’s health ministry, to supply its Gaucher treatment Uplyso.
The seven-year agreement is worth approx. $40 million a year, totaling at $280 million.
Related posts
New AI-Powered Robot Specializes In Picking Citrus Fruit
September 17, 2024
Researchers Develop New Early Identification For Parkinson’s
September 16, 2024
AI Dubbing Startup Launches API Integration, Singing Feature
September 16, 2024
Water-From-Air Tech Placed At Bedouin Sustainable Farming Initiative
September 15, 2024
Facebook comments